NCT00925301View on ClinicalTrials.gov

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 23, 2009

Primary Completion Date

June 12, 2012

Study Completion Date

January 29, 2014

Conditions
Fabry Disease
Interventions
DRUG

migalastat hydrochloride

Oral capsule QOD

DRUG

Placebo

Oral capsule QOD

Trial Locations (28)

3050

Parkville

5006

Adelaide

10032

New York

11451

Cairo

15224

Pittsburgh

22152

Springfield

30033

Decatur

49525

Grand Rapids

50009

Zaragoza

60611

Chicago

66160

Kansas City

75226

Dallas

84132

Salt Lake City

90048

Los Angeles

92380

Garches

94143

San Francisco

98195

Seattle

02114

Boston

B1629ODT

Buenos Aires

90035-903

Porto Alegre

14048-900

São Paulo

H4J 1C5

Montreal

DK-2100

Copenhagen

00168

Roma

04-628

Warsaw

08025

Barcelona

06500

Ankara

M6 8HD

Salford

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY